Mass General Brigham (MGB) and other health systems are deploying artificial intelligence to shorten timelines for bringing new therapies to patients, the Healthcare IT News video reports. AI analyzes electronic health records and other real-world data to identify eligible trial candidates faster, optimize trial design, surface predictive biomarkers and accelerate recruitment and go-no-go decisions.
The video highlights collaboration among health systems, biopharma and regulators to validate models, manage safety, and address bias and privacy concerns. Experts stress the need for operational integration, transparent performance metrics and federated data-sharing to scale benefits while preserving patient trust. Early pilots at MGB and elsewhere reportedly reduced lead times and improved patient matching, pointing to wider clinical and commercial implications.
